Capecitabine

About

Therapy type: Chemotherapy

Therapy strategy: Thymidylate synthase inhibition

Mappings

NCI Thesaurus: Capecitabine (ncit:C1794)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Capecitabine FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Margetuximab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib FDA
Sensitivity (+) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab FDA
Sensitivity (+) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib FDA
Sensitivity (+) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib HC
Sensitivity (+) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab HC
Sensitivity (+) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab FDA
Sensitivity (+) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab FDA
Sensitivity (+) PD-L1 (CPS) >= 1 Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab FDA